Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Br J Pharmacol. 2022 Feb 10;179(11):2647–2658. doi: 10.1111/bph.15762

Figure 3. Central effects of the NOP antagonist LY2817412 on nicotine self-administration in VTA, NAC and CeA in NOP (+/+) rats.

Figure 3.

(A) Number of responses (infusions and total number of active and inactive lever presses) following central LY2817412 injection (0.0, 3.0 and 6.0 μg/μl) in VTA (n = 9), (B) NAc (n = 8) and (C) CeA (n = 11) in NOP (+/+) rats. ***p < 0.001 vs. 0.0 μg/μl vs 3.0 μg/μl and **p < 0.01 vs. 0.0 μg/μl vs 6.0 μg/μl. Values represent mean (± SEM).